Abstracts Archive - Page 991 of 2607 - ACR Meeting Abstracts

Abstract Number: 763 • 2019 ACR/ARP Annual Meeting
Treatment Efficacy Evaluation of Leflunomide by Regulating Macrophages in Takayasu Arteritis
Xiaomeng Cui¹, Xiaomin Dai ¹, Xiufang Kong ², Rongyi Chen ¹, Lili Ma ¹, Ying Sun ³ and Lindi Jiang ¹, ¹Zhongshan hospital, Fudan University, Shanghai, China (People's Republic), ²University of Michigan & Fudan University, Ann Arbor, MI, ³Department of Rheumatology, Zhongshan Hospital, Fudan University, Shanghai, P. R. China, Shanghai
Background/Purpose: To evaluate the efficacy and safety of leflunomide (LEF) for active Chinese Takayasu Arteritis (TA) patients in induction therapy compared with cyclophosphamide (CYC) and…
Abstract Number: 764 • 2019 ACR/ARP Annual Meeting
The Clinical and Angiographic Features of Chinese Takayasu’s Arteritis Patients: A Cohort Study of 591 Patients in 6 Years
Yunjiao Yang¹, Jing Li ², Xinping Tian ¹ and Xiaofeng Zeng ¹, ¹Peking Union Medical College Hospital, Beijing, China (People's Republic), ²Department of Rheumatology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Medical College, Beijing
Background/Purpose: To investigate the clinical and angiographic features of 591 Chinese Takayasu’s arteritis (TAK) patientsMethods: Clinical and angiographic findings of 591 Chinese TAK patients enrolled…
Abstract Number: 765 • 2019 ACR/ARP Annual Meeting
Application of Different Sets of Classification/diagnostic Criteria for Polymyalgia Rheumatica: Single Center Study of 100 Patients
DIANA PRIETO- PENA¹, Mónica Calderón-Goercke ², Iñigo Gonzalez-Mazon ¹, Jose Luis Martín-Varillas ³, Lara Sanchez-Bilbao ³, Belén Atienza-Mateo ³, Miguel Angel González-Gay ⁴ and Ricardo Blanco ³, ¹Rheumatology, Hospital Universitario Marques de Valdecilla, Santander, Cantabria, Spain, ²Hospital Marqués de Valdecilla, Santander, Cantabria, Spain, ³Rheumatology, Hospital Universitario Marques de Valdecilla, Santander, Spain, ⁴Universidad de Cantabria and IDIVAL, Hospital Universitario Marqués de Valdecilla, Santander, Spain
Background/Purpose: Polymyalgia rheumatica (PMR) diagnosis is based on clinical and analytical features characterized by shoulder and pelvic girdle pain associated with elevated acute phase reactants.…
Abstract Number: 766 • 2019 ACR/ARP Annual Meeting
Predictors of Long-term Therapy with Glucocorticoid in Polymyalgia Rheumatica
Akiko Aoki¹, Hiroshi Kobayashi ¹ and Hiroshi Oka ¹, ¹Tokyo Medical University Hachioji Medical Center, Hachioji, Tokyo, Japan
Background/Purpose: Clinical symptoms of polymyalgia rheumatica (PMR) are improved by low-dose glucocorticoids (GC), but relapses and long-term GC therapy are common. 2015 EULAR/ACR recommendations suggest…
Abstract Number: 767 • 2019 ACR/ARP Annual Meeting
Outcome Measures in Large-Vessel Vasculitis: Relationships Between Patient, Physician, Imaging, and Laboratory-Based Domains
Casey A. Rimland¹, Kaitlin Quinn ², Joel S. Rosenblum ³, Mollie Schwartz ⁴, K Bates Gribbons ⁵, Elaine Novakovich ⁶, Antoine Sreih ⁷, Peter Merkel ⁷, Mark A. Ahlman ⁸ and Peter C. Grayson ⁹, ¹National Institute of Arthritis, Musculoskeletal and Skin Disease (NIAMS), Bethesda, MD, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC, Chapel Hill, NC, ²Georgetown University Hospital/National Institutes of Health, Washington, DC, ³National Institute of Arthritis, Musculoskeletal and Skin Disease (NIAMS), Bethesda, MD, Bethesda, MD, ⁴University of Maryland, Baltimore, MD, ⁵National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ⁶National Institutes of Health, Bethesda, MD, ⁷University of Pennsylvania, Philadelphia, PA, ⁸Radiology and Imaging Sciences, National Institutes of Health, Bethesda, MD, Bethesda, MD, ⁹National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) of the National Institutes of Health, Bethesda, MD, Bethesda, MD
Background/Purpose: Large-vessel vasculitis (LVV) is characterized by inflammation of the aorta and its major branches. The most common forms of LVV include giant cell arteritis…
Abstract Number: 768 • 2019 ACR/ARP Annual Meeting
Angiographic Patterns and Changes in Arterial Lesions in Patients with Behcet’s Disease
Su Jin Choi¹, So Hye Nam ¹, Jung Sun Lee ¹, Doo-Ho Lim ², Ji Seon Oh ³, Seokchan Hong ¹, Yong-Gil Kim ¹, Chang-Keun Lee ¹ and Bin Yoo ¹, ¹Division of Rheumatology, Department of Internal Medicine, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Republic of Korea, ²Division of Rheumatology, Department of Internal Medicine, Ulsan University Hospital, Ulsan, Republic of Korea, ³Department of Biomedical Informatics, Asan Medical Center, Seoul, Korea, Seoul, Republic of Korea
Background/Purpose: Arterial involvement is a manifestation of systemic vasculitis in Behçet’s disease (BD). Changes to BD arterial lesions over time can help predict patient prognosis.…
Abstract Number: 769 • 2019 ACR/ARP Annual Meeting
Damage in Takayasu‘s Arteritis Is Associated with Age at Symptom-onset, Disease-duration and Corticosteroid Dose but Not Relapse in Routine Follow-up
Sema Kaymaz-Tahra¹, Fatma Alibaz-Oner ² and Haner Direskeneli ³, ¹Marmara University School of Medicine, Division of Rheumatology, Istanbul, Istanbul, Turkey, ²Marmara University Faculty of Medicine,Department of Rheumatology,Istanbul,Turkey, Istanbul, Turkey, ³Marmara University, School of Medicine, Division of Rheumatology, Istanbul, Turkey
Background/Purpose: As a large-vessel vasculitis of young-age group, Takayasu‘s arteritis (TAK) have a high morbidity and mortality caused by the disease or treatments such as…
Abstract Number: 770 • 2019 ACR/ARP Annual Meeting
Involvement of Iliofemoral and Axillary Arteries in PET-CT May Be Associated with Atherosclerotic Risk Factors in Takayasu’s Arteritis
Sema Kaymaz-Tahra¹, Salih Ozguven ², Ali Ugur Unal ³, Fatma Alibaz-Oner ⁴, Tunc Ones ², Tanju Yusuf Erdil ² and Haner Direskeneli ⁵, ¹Marmara University School of Medicine, Division of Rheumatology, Istanbul, Istanbul, Turkey, ²Marmara University Faculty of Medicine, Nuclear Medicine, Istanbul, Turkey, ³Marmara University Faculty of Medicine, Rheumatology, Istanbul, Turkey, ⁴Marmara University Faculty of Medicine,Department of Rheumatology,Istanbul,Turkey, Istanbul, Turkey, ⁵Marmara University, School of Medicine, Division of Rheumatology, Istanbul, Turkey
Background/Purpose: FDG-PET-CT is recommended as one of the imaging modalities for the diagnosis and monitoring of primary large-vessel vasculitis (LVV), such as Takayasu’s arteritis (TAK).…
Abstract Number: 771 • 2019 ACR/ARP Annual Meeting
Von Willebrand Factor Is Localized in the Extravascular Tissue of Patients with Juvenile Scleroderma
Natalia Vasquez-Canizares¹, Beamon Agarwal ², Tamar Rubinstein ³, Dawn Wahezi ⁴ and Morayma Reyes Gil ⁵, ¹Children's Hospital at Montefiore, Bronx, NY, ²GenomeRxUS LLC, Providence, PA, ³Children's Hospital at Montefiore/Albert Einstein College of Medicine, Bronx, NY, ⁴Children’s Hospital at Montefiore, New York, ⁵Montefiore Medical Center/Albert Einstein College of Medicine, Bronx
Background/Purpose: Von Willebrand Factor (VWF) is a glycoprotein synthesized in endothelial cells and megakaryocytes that has an essential role in primary hemostasis. There is increasing…
Abstract Number: 772 • 2019 ACR/ARP Annual Meeting
The Study of the Novel G87V Mutation in the TNFRSF1A Gene Identified in a Family with TNF Receptor-Associated Periodic Syndrome (TRAPS)
Shoko Tsuji¹, Hidenori Matsuzaki ², Masanori Iseki ³, Akiko Nagasu ¹, Hiroyasu Hirano ¹, Katsuhiko Ishihara ⁴, Naoyasu Ueda ⁵, Yoshitaka Honda ⁶, Takahiko Horiuchi ⁷, Ryuta Nishikomori ⁸, Yoshitaka Morita ¹ and Tomoyuki Mukai ⁹, ¹Department of Rheumatology, Kawasaki Medical School, Kurashiki, Okayama, Japan, ²Department of Life Sciences, Faculty of Life and Environmental Sciences, Prefectural University of Hiroshima, shobara, Hiroshima, Japan, ³Department of Immunology and Molecular Genetics, Kawasaki Medical School, Kurashiki, Okayama, Japan, ⁴Department of Immunology and Molecular Genetics, Kurashiki, Okayama, Japan, ⁵Department of Internal Medicine, Miyazaki Prefectural Miyazaki Hospital, Miyazaki, Japan, ⁶Department of Pediatrics, Kyoto University Graduate School of Medicine, Kyoto, Japan, ⁷Department of Internal Medicine, Kyushu University Beppu Hospital, Beppu, Japan, Beppu, Japan, ⁸Department of Pediatrics and Child Health, Kurume University School of Medicine, Kurume, Fukuoka, Japan, ⁹Department of Rheumatology, Kawasaki medical School, Kurashiki, Okayama, Okayama, Japan
Background/Purpose: TNF Receptor-Associated Periodic Syndrome (TRAPS) is one of the autoinflammatory diseases. TRAPS is caused by heterozygous mutations in the TNFRSF1A gene. Although more than…
Abstract Number: 773 • 2019 ACR/ARP Annual Meeting
Chondrocytes Influence Fibroblast-like Synoviocytes from Patients with Juvenile Idiopathic Arthritis, Through the Abrogation of TGFβ Signaling, to Delay Cell Differentiation and Maturation
Megan Simonds ¹, Amanda Schlefman ¹, Suzanne McCahan ¹, Kathleen Sullivan ², Carlos Rose ³ and AnneMarie Brescia³, ¹Nemours Biomedical Research, Wilmington, DE, ²Children's Hospital of Philadelphia, Philadelphia, PA, ³Nemours/ Alfred I DuPont Hospital for Children, Wilmington, DE
Background/Purpose: Progression of Juvenile Idiopathic Arthritis (JIA) can lead to growth disturbances in affected joints. Fibroblast-like synoviocytes (FLS) play a key role in the pathogenesis…
Abstract Number: 774 • 2019 ACR/ARP Annual Meeting
Identical T Cell Clones Identified over Time in the Joints of Oligoarticular Juvenile Idiopathic Arthritis Patients
Amelie Jule¹, Kacie Hoyt ², Margaret Chang ³, Fatma Dedeoglu ², Melissa Hazen ¹, Peter Nigrovic ⁴ and Lauren Henderson ¹, ¹Boston Children's Hospital, Boston, MA, ²Boston Children's Hospital, Boston, ³Division of Immunology, Boston Children's Hospital, Boston, ⁴Department of Medicine, Division of Rheumatology, Immunology and Allergy, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA ; Department of Medicine, Division of Immunology, Boston Children’s Hospital, Harvard Medical School, Boston, MA, USA., Boston
Background/Purpose: Oligoarticular juvenile idiopathic arthritis (oligo JIA) is characterized by arthritis in a few joints (fewer than 5) with recurrent flares of inflammation, often in…
Abstract Number: 775 • 2019 ACR/ARP Annual Meeting
Cutaneous Gene Expression Signatures in Juvenile Myositis Reveal a Prominent IFN Signature in Lesional Skin
Jessica Turnier¹, Celine Berthier ¹, Lam Tsoi ¹, Lori Lowe ¹, Gabrielle Morgan ², Johann Gudjonsson ¹, Lauren Pachman ² and J. Michelle Kahlenberg ¹, ¹University of Michigan, Ann Arbor, MI, ²Northwestern University, Chicago
Background/Purpose: Skin inflammation can herald systemic disease manifestations and disease chronicity in juvenile myositis (JM), yet we lack an understanding of the pathogenic mechanisms driving…
Abstract Number: 776 • 2019 ACR/ARP Annual Meeting
Genetic Signatures Support Inflammation Driven Fibrosis in Localized Scleroderma
Christina Schutt¹, Emily Mirizio ², Claudia Salgado ³, Miguel Reyes-Mugica ³, Kaila L. Schollaert ² and Kathryn Torok ³, ¹UPMC Children's Hospital of Pittsburgh, Pittsburgh, PA, ²University of Pittsburgh, Pittsburgh, ³UPMC Children's Hospital of Pittsburgh, Pittsburgh
Background/Purpose: Localized scleroderma (LS) is a progressive autoimmune disease of the skin and underlying tissue that is characterized by an initial inflammatory infiltration which is…
Abstract Number: 777 • 2019 ACR/ARP Annual Meeting
Interferon Response Gene Expression Differs in Whole Blood, Peripheral Blood Mononuclear Cells, Monocytes, Dendritic Cells, Neutrophils, and Skin Tissue in Patients with the Autoinflammatory Interferonopathies, CANDLE and SAVI
Jacob Mitchell¹, Sara Alehashemi ², Bernadette Marrero ³, Yan Huang ⁴, Lena Bichell ⁵, Gina Montealegre Sanchez ¹, Raphaela Goldbach-Mansky ² and Adriana de Jesus ¹, ¹Translational Autoinflammatory Disease Section/NIAID/NIH, Bethesda, ²Translational Autoinflammatory Diseases Section/NIAID/NIH, Bethesda, MD, ³Computational Systems Biology Section/NIAID/NIH, Bethesda, ⁴Translational Autoinflammatory Disease Section/NIAID/NIH, Bethesda, MD, ⁵Translational Autoinflammatory Diseases Section/NIAID/NIH, Bethesda
Background/Purpose: The disease progression of patients (pts.) with type-I interferon (IFN)-mediated diseases undergoing treatment with JAK1 and JAK2 inhibitors is monitored in part by measuring…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].